Lovotibeglogene autotemcel (Lyfgenia; Bluebird Bio Inc.) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.
Lovotibeglogene autotemcel (Lyfgenia; Bluebird Bio Inc.) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.